<DOC>
	<DOCNO>NCT02939183</DOCNO>
	<brief_summary>A study evaluate two new formulation oprozomib plus pomalidomide dexamethasone patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Phase 1b Study Evaluating OPomD Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>A multicenter , non-randomized , open-label , dose-exploration study evaluate two new formulation oprozomib plus pomalidomide dexamethasone patient relapse refractory multiple myeloma . The study conduct two part . Part 1 evaluate formulation oprozomib combination dexamethasone . Part 2 evaluate formulation oprozomib administer increase dose level ( dose escalation ) combination pomalidomide dexamethasone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion Subject must pathologically document , definitively diagnose , multiple myeloma relapse , refractory progressive disease least 2 line therapy multiple myeloma . Prior therapeutic treatment regimen must include proteasome inhibitor lenalidomide . Subject must willing able undergo bone marrow aspirate per protocol ( without bone marrow biopsy per institutional guideline ) . Measurable disease ( assess within 28 day prior day 1 ) Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; = 2 . Other Inclusion Criteria May Apply Exclusion Criteria Currently receive treatment another investigational device drug study , less 28 day since end treatment another investigational device drug study . Previously receive allogeneic stem cell transplant occurrence one following : receive transplant within 6 month prior study day 1 ; receive immunosuppressive therapy within last 3 month prior study day 1 ; sign symptom acute chronic graftversushost disease . Autologous stem cell transplant &lt; 90 day prior study day 1 . Multiple myeloma IgM subtype . POEMs syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) . Plasma cell leukemia ( &gt; 2.0 X109/L circulate plasma cell standard differential ) . Waldenstrom 's macroglobulinemia . Other Exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>